Popular Articles

FDA Confirms E. Coli O157:H7 In Prepackaged Nestlç© Toll House Refrigerated Cookie Dough
Today, the U.S. Food and Drug Administration announced that it has found E. coli O157:H7 (a bacterium that can cause serious food borne illness) in a sample of prepackaged Nestlç© Toll House refrigerated cookie dough currently under recall by the manufacturer and marketer, Nestlç© USA. The contaminated sample was collected at Nestlç©"s facility in Danville, Va. on June 25, 2009.

Oregon Legislature Passes Statewide Health Reform Bills
The Oregon state legislature cleared two reform bills that passed its House of Representatives earlier this week, the Portland Oregonian reports. One bill will tax insurers and hospitals up to $500 million over two years to provide "health coverage for 80,000 uninsured children and an additional 35,000 uninsured low-income adults and put the state on a path toward covering all of its more than 600,000 uninsured residents." The state will leverage as much as $1 billion in federal matching funds. "Some of the federal money will be used to pay hospitals what they pay in taxes. Insurers also will get a portion of their tax money back," the Oregonian reports.
News of the day
Sotomayor Calls Roe 'Settled Law,' Says Health Of Woman Must Be Considered
During the second day of her Senate Judiciary Committee confirmation hearings, Supreme Court nominee Sonia Sotomayor said she views the 1973 Roe v. Wade decision legalizing abortion in the U.S. as settled law reaffirmed by subsequent Supreme Court rulings, the Washington Post reports (Goldstein et al., Washington Post, 7/15). At Tuesday"s hearing, lawmakers pressed Sotomayor on her views regarding abortion rights and Supreme Court precedent, the New York Times reports. She told committee members that the contraception rights case that is the foundation for Roe was "the precedent of the court, so it is settled law." She also said the 1992 ruling in Casey v. Planned Parenthood "reaffirmed the core holding of Roe," adding, "That is the precedent of the court and settled law in terms of the holding of the court" (Savage, New York Times, 7/15). Sotomayor said that "there is a right of privacy" and that the Supreme Court "has found it in various places in the Constitution." She cited the Fourth Amendment protection against unreasonable search and seizure and the 14th Amendment guaranteeing equal protection of the law (AP/Yahoo! News, 7/14).Sen. Orrin Hatch (R-Utah) asked Sotomayor if she considered the 2007 ruling in Gonzales v. Carhart an example of settled law. In the case, the court voted 5-4 to uphold the Partial-Birth Abortion Ban Act of 2003. The ruling was the first time since Roe that the court upheld an abortion restriction that made no exception for the health of the woman, the Times reports. In her response, Sotomayor said that "[a]ll precedent of the Supreme Court I consider settled law, subject to the deference the doctrine of stare decisis would counsel," although she did not address the health exception component of the Gonzales case.Sen. Dianne Feinstein (D-Calif.) later pressed Sotomayor to elaborate on her views on Gonzales. Feinstein noted that at least seven Supreme Court rulings prior to the 2007 case stated that abortion laws "cannot put a woman"s health at risk." She added that Gonzales "essentially removed this basic constitutional right for women." Feinstein asked Sotomayor, "When there are multiple precedents and a question arises, are all the previous decisions discarded, or should the court re-examine all the cases on point?" Sotomayor replied that she does not consider Gonzales to be a precedent making it settled law that health exceptions for abortion laws are constitutionally unnecessary. She said, "That was, I don"t believe, a rejection of its prior precedents," which are "still precedents of the court." Sotomayor added that the "health and welfare of a woman must be -- must be a compelling consideration." Feinstein pressed Sotomayor to clarify that she meant that it is still settled that abortion restrictions must have health exceptions. Sotomayor said, "It has been a part of the court"s jurisprudence and a part of its precedents. Those precedents must be given deference in any situation that arises before the court" (New York Times, 7/15).Sen. Lindsey Graham (R-S.C.) asked Sotomayor if the Constitution prohibits Congress or state legislatures "from defining life or regulating the rights of the unborn or protecting the right of the unborn in the first trimester?" Sotomayor began to cite the 14th Amendment to answer the question. Graham interrupted, asking, "[I]s there÷ anything in the document written about abortion?" Sotomayor said the "word "abortion" is not used in the Constitution, but the Constitution does have a broad provision concerning a liberty provision under the due process" clause (Holman, "NewsHour with Jim Lehrer," PBS, 7/14).Graham also asked Sotomayor about her work with the Puerto Rican Legal Defense and Education Fund, which had submitted legal briefs in the past that supported public funding for abortion coverage for low-income women. Sotomayor served on the group"s board from 1980 to 1992. She said that she "wasn"t aware of what was said in those briefs." She noted that she had served on the board but was not a lawyer for the gro
Oncology

The Automation Partnership's First Project To Automate Manufacture Of 3D Tissue Constructs

The Automation Partnership (TAP), a world leader in the design and development of innovative advanced automation for life science applications, announced it is collaborating with world leading academics on the prestigious, Technology Strategy Board funded, RAFT (Rapid Automated Fabrication of Tissues) Project to develop and commercialise novel technology for rapid production of 3D tissues, which have the potential to transform drug discovery and regenerative medicine. The three-year RAFT Project initially aims to manufacture 3D human corneal tissue using corneal limbal stem cells, to determine if this is a viable method of producing a range of different tissue types. Scientists on the RAFT Project at UCL (University College London) will work on demonstrating pre-clinical proof of concept of the efficacy of these tissues for corneal regeneration. Complex 3D tissues can be produced in less than one hour by mixing cells with collagen, casting the gel into a mould then compressing it to give a sheet with properties very like natural tissue. The 3D structure provides cells with a more natural microenvironment; multiple layers with different cell types can be made with surface features that mimic the stem cell niche and support cell growth and differentiation. Since production of the tissues will be automated the size, shape, thickness and cell density can all be controlled - and complex features such as capillary like channels can be engineered into the tissues. This technology allows high quality and consistent manufacturing of tissues for therapeutic use, such as replacement skin; in cell biology by providing 3D collagen matrices for studying cell behaviour or in drug discovery applications including toxicity testing by generating skin, cornea and other models. Dr Rosemary Drake, CSO at TAP stated: "We are delighted to be working with eminent academics to commercialise this unique tissue fabrication process. We have licensed the use of this exciting technology from UCL because we are so confident it could be used to produce a number of different 3D tissue types and are seeking additional partners from pharmaceutical or cell culture companies with whom we can develop cell culture, drug discovery and therapeutic applications where more authentic tissues are required." David Newble, TAP"s CEO, added: "The significant industrial academic collaboration which has begun between TAP and UCL will make transformational science available for rapid, reproducible processing of commercially important tissues and could potentially, have a major impact on the future of drug discovery, development and regenerative medicine." About The Automation Partnership The Automation Partnership (TAP) is a world leader in the design, development and manufacture of advanced large-scale automation systems for the life science research industry. TAP specialises in automation for cell culture, biological sample management, compound management and ultra high throughput screening applications. TAP"s systems are installed in the world"s top pharmaceutical and biotechnology companies; key service providers and leading research institutions including: Amgen, AstraZeneca, ATCC, Bristol-Myers Squibb, Exelixis, Laboratoires Fournier, Loughborough University, GlaxoSmithKline, Max Planck Institute, Merck, MedImmune, Novartis, Oxford University, Pfizer, Roche, Sanofi Aventis, Stem Cell Sciences, UK Biobank and Wyeth. TAP, founded in 1988, is a private company with headquarters in Royston near Cambridge, UK and a US sales and support office in Wilmington, Delaware. The Company, which employs over 180 staff, continues to grow by developing market driven automation products from standalone systems to multi-million pound drug discovery facilities. About the Rapid Automated Fabrication of Tissues Project The Rapid Automated Fabrication of Tissues (RAFT) Project is an industrial-academic collaboration in which TAP is the lead industrial partner and includes some of the world"s leading experts from the UCL Institute of Ophthalmology and the Tissue Repair & Engineering Centre (TREC) at the UCL Institute of Orthopaedics & Musculoskeletal Science. The project which has ÷£1.3 million funding from the UK"s Technology Strategy Board (TSB) aims to develop a commercial method for producing novel, cost-effective 3D tissues. The Automation Partnership


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):